1、 GROSSER R,CHERKASSKY L,CHINTALA N,et al.Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors[J].Cancer Cell,2019,36(5):471-482. GROSSER R,CHERKASSKY L,CHINTALA N,et al.Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors[J].Cancer Cell,2019,36(5):471-482.
2、 SHOLL L M,HIRSCH F R,HWANG D,et al.The promises and challenges of tumor mutation burden as an immunotherapy biomarker:A perspective from the international association for the study of lung cancer pathology committee[J].J Thorac Oncol,2020,15(9):1409-1424. SHOLL L M,HIRSCH F R,HWANG D,et al.The promises and challenges of tumor mutation burden as an immunotherapy biomarker:A perspective from the international association for the study of lung cancer pathology committee[J].J Thorac Oncol,2020,15(9):1409-1424.
3、 LENZ H J,OU F S,VENOOK A P,et al.Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer:Results from CALGB/SWOG 80405(alliance)[J].J Clin Oncol,2019,37(22):1876-1885. LENZ H J,OU F S,VENOOK A P,et al.Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer:Results from CALGB/SWOG 80405(alliance)[J].J Clin Oncol,2019,37(22):1876-1885.
4、 GUINNEY J,DIENSTMANN R,WANG X,et al.The consensus molecular subtypes of colorectal cancer[J].Nat Med,2015,21(11):1350-1356. GUINNEY J,DIENSTMANN R,WANG X,et al.The consensus molecular subtypes of colorectal cancer[J].Nat Med,2015,21(11):1350-1356.
5、 LI K,WANG F,YANG Z N,et al.TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation[J].Nat Commun,2020,11(1):6316. LI K,WANG F,YANG Z N,et al.TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation[J].Nat Commun,2020,11(1):6316.
6、 LIANG K,O’CONNOR C,VEIGA J P,et al.TRIB2 regulates normal and stress-induced thymocyte proliferation[J].Cell Discov,2016(2):15050. LIANG K,O’CONNOR C,VEIGA J P,et al.TRIB2 regulates normal and stress-induced thymocyte proliferation[J].Cell Discov,2016(2):15050.
7、 LU H,SHI T,WANG M,et al.B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells[J].Oncoimmunology,2020,9(1):1748991. LU H,SHI T,WANG M,et al.B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells[J].Oncoimmunology,2020,9(1):1748991.
8、 WANG H,GAO Y,VAFAEI S,et al.A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy[J].Mol Ther Nucleic Acids,2022(27):427-438. WANG H,GAO Y,VAFAEI S,et al.A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy[J].Mol Ther Nucleic Acids,2022(27):427-438.
9、 NEWMAN A M,LIU C L,GREEN M R,et al.Robust enumeration of cell subsets from tissue expression profiles[J].Nat Methods,2015,12(5):453-457. NEWMAN A M,LIU C L,GREEN M R,et al.Robust enumeration of cell subsets from tissue expression profiles[J].Nat Methods,2015,12(5):453-457.
10、 YOSHIHARA K,SHAHMORADGOLI M,MARTíNEZ E,et al.Inferring tumour purity and stromal and immune cell admixture from expression data[J].Nat Commun,2013(4):2612. YOSHIHARA K,SHAHMORADGOLI M,MARTíNEZ E,et al.Inferring tumour purity and stromal and immune cell admixture from expression data[J].Nat Commun,2013(4):2612.
11、 HOU Z,GUO K,SUN X,et al.TRIB2 functions as novel oncogene in colorectal cancer by blocking cellular senescence through AP4/p21 signaling[J].Mol Cancer,2018,17(1):172. HOU Z,GUO K,SUN X,et al.TRIB2 functions as novel oncogene in colorectal cancer by blocking cellular senescence through AP4/p21 signaling[J].Mol Cancer,2018,17(1):172.
12、 MAI Z,GUO K,SUN X,et al.Expression and related mechanisms of miR-100 and TRIB2 in COPD patients[J].J Healthc Eng,2022(2022):6556208. MAI Z,GUO K,SUN X,et al.Expression and related mechanisms of miR-100 and TRIB2 in COPD patients[J].J Healthc Eng,2022(2022):6556208.
13、 GUO S,CHEN Y,XUE X,et al.TRIB2 desensitizes ferroptosis via βTrCP-mediated TFRC ubiquitiantion in liver cancer cells[J].Cell Death Discov,2021,7(1):196. GUO S,CHEN Y,XUE X,et al.TRIB2 desensitizes ferroptosis via βTrCP-mediated TFRC ubiquitiantion in liver cancer cells[J].Cell Death Discov,2021,7(1):196.
14、 MAYORAL-VARO V,JIMéNEZ L,LINK W,The critical role of TRIB2 in cancer and therapy resistance[J].Cancers(Basel),2021,13(11):2701. MAYORAL-VARO V,JIMéNEZ L,LINK W,The critical role of TRIB2 in cancer and therapy resistance[J].Cancers(Basel),2021,13(11):2701.
15、 ROME K S,STEIN S J,KURACHI M,et al.Trib1 regulates T cell differentiation during chronic infection by restraining the effector program[J].J Exp Med,2020,217(5):e20190888. ROME K S,STEIN S J,KURACHI M,et al.Trib1 regulates T cell differentiation during chronic infection by restraining the effector program[J].J Exp Med,2020,217(5):e20190888.
16、 LIU Y R,SONG D D,LIANG D M,et al.Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession[J].Cell Death Discov,2022,8(1):306. LIU Y R,SONG D D,LIANG D M,et al.Oncogenic TRIB2 interacts with and regulates PKM2 to promote aerobic glycolysis and lung cancer cell procession[J].Cell Death Discov,2022,8(1):306.
17、 LIU I D,WILLIS N S,CRAIG J C,et al.Interventions for idiopathic steroid-resistant nephrotic syndrome in children[J].Cochrane Database Syst Rev,2019,2019(11):CD003594. LIU I D,WILLIS N S,CRAIG J C,et al.Interventions for idiopathic steroid-resistant nephrotic syndrome in children[J].Cochrane Database Syst Rev,2019,2019(11):CD003594.
18、 OLIVEIRA A F,BRETES L,FURTADO I.Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer[J].Front Oncol,2019(9):396. OLIVEIRA A F,BRETES L,FURTADO I.Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer[J].Front Oncol,2019(9):396.
19、 PETERSON C,DENLINGER N,YANG Y.Recent advances and challenges in cancer immunotherapy[J].Cancers(Basel),2022,14(16):3972. PETERSON C,DENLINGER N,YANG Y.Recent advances and challenges in cancer immunotherapy[J].Cancers(Basel),2022,14(16):3972.
20、 NTAVATZIKOS A,SPATHIS A,PATAPIS P,et al.TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer[J].World J Gastrointest Oncol,2019,11(7):551-566. NTAVATZIKOS A,SPATHIS A,PATAPIS P,et al.TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer[J].World J Gastrointest Oncol,2019,11(7):551-566.
21、 BREAKSTONE R.Colon cancer and immunotherapy-can we go beyond microsatellite instability?[J].Transl Gastroenterol Hepatol,2021(6):12. BREAKSTONE R.Colon cancer and immunotherapy-can we go beyond microsatellite instability?[J].Transl Gastroenterol Hepatol,2021(6):12.
22、 BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263. BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
23、 黄庆,索彩霞,何凤,等.结直肠癌的早期诊断策略和治疗进展[J].广州医药,2024.55(1):1-8. 黄庆,索彩霞,何凤,等.结直肠癌的早期诊断策略和治疗进展[J].广州医药,2024.55(1):1-8.
24、 SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34. SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34.
